Novavax announced Monday that it has formally submitted a request for the U.S. Food and Drug Administration to authorize its coronavirus vaccine for emergency use in the United States.
The request is based on data that includes the results of two large clinical trials that demonstrated an overall efficacy of approximately 90 per cent and a "reassuring safety profile," according to the company.
"We believe our vaccine offers a differentiated option built on a well-understood protein-based vaccine platform that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic," Stanley Erck, Novavax’s president and chief executive officer, said in the announcement Monday.
- Newsletter sign-up: Get The COVID-19 Brief sent to your inbox
Novavax announced in June that its vaccine candidate was found to have an overall efficacy of 90.4 per cent in a Phase 3 trial conducted across the United States and Mexico; the trial took place before the Omicron variant dominated in the United States.
Then in December, the company said that it had finished its final submission package to the FDA for emergency use authorization (EUA) of the vaccine, called NVX-CoV2373.
The vaccine can be stored at normal refrigeration temperatures, between 2 and 8 C, and has a shelfxjmtzyw life of about nine months, according to the company. Erck told CNN in November that if the FDA gives the green light for the EUA, the first 100 million doses of the protein-based vaccine will be ready to ship following authorization.
Novavax’s vaccine — administered as two doses, three weeks apart — is made using small, laboratory-built pieces of the coronavirus to stimulate immunity, which is a more traditional approach for vaccine development that some people may be more familiar or comfortable with compared with the mRNA vaccines made by Moderna or Pfizer.
"In the U.S., the primary market I think in 2022 is going to be to supply a vaccine, our normal two-dose regimen, to a lot of people who have been hesitant to get other vaccines," Erck said in November. "And to provide a booster."
The FDA has previously authorized vaccines made by Pfizer, Moderna and Johnson & Johnson for emergency use in the United States. The Pfizer vaccine is now approved for use in people age 16 and older and the Moderna vaccines is approved for adults.
In November, Indonesia became the first country to grant emergency use authorization of Novavax’s vaccine. Since then, South Korea’s Ministry of Food and Drug Safety has approved the vaccine, Australia’s Therapeutic Goods Administration has granted approval for provisional registration of the vaccine and the Drugs Controller General of India has granted emergency use authorization of the vaccine.
Novavax so far has applied for authorization in several other countries, including the United Kingdom, Canada, New Zealand, the European Union and the Philippines.
RELATED IMAGESview larger image
Novavax is seeking FDA emergency use authorization of its coronavirus vaccine. Pictured is a potential coronavirus vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020. (Andrew Caballero-Reynolds/AFP/Getty Images)
